Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596895 · ClinicalTrials.gov registry record · Phase 2
Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer
A Phase 2 study of Biochemical Recurrent Prostate Cancer, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00596895: Completed Phase 2 study of Biochemical Recurrent Prostate Cancer, sponsored by University of Florida.
NCT00596895 is a Phase 2 study of Biochemical Recurrent Prostate Cancer that has completed, run by University of Florida. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00596895, a Phase 2 study of Biochemical Recurrent Prostate Cancer, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Outcome Measures: Decrease in rate of serum PSA rise Secondary Outcome Measures: Adherence to treatment regimens Quality of life as assessed by FACT-P at baseline and at 12 months of treatment Modulation of serum testosterone,isoflavone metabolites, and cholesterol Estimated Enrollment: 27 Study Start Date: November 2003 Estimated Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Isoflavone
Study Locations (1)
Florida
- University of Florida Shands - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
What the finished NCT00596895 record still lists
NCT00596895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Biochemical Recurrent Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Isoflavone is the first listed.
NCT00596895 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00596895 about?
NCT00596895 is a clinical study titled "Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer". Primary Outcome Measures: Decrease in rate of serum PSA rise Secondary Outcome Measures: Adherence to treatment regimens Quality of life as assessed by FACT-P at baseline and at 12 months of treatment Modulation of serum testosterone,isoflavone metabolites, and cholesterol Estimated Enrollment...
What is the current status of trial NCT00596895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-11. Estimated completion is 2007-11.
What conditions does trial NCT00596895 study?
This clinical trial studies the following conditions: Biochemical Recurrent Prostate Cancer.
What interventions are being tested in trial NCT00596895?
The interventions under investigation include: Isoflavone (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00596895?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00596895 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biochemical Recurrent Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00596895's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia